Supplements
boswellia is safe at supplement doses
In plain terms: Is boswellia safe to take?
Part of: 🧪 boswellia
Generally yes — it's well-tolerated in trials, usually gentler on the stomach than anti-inflammatory drugs, with mild digestive upset the main complaint. Long-term data are thinner.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Generally well-tolerated. Across OA trials boswellia has a favourable safety profile — often better GI tolerability than NSAIDs — with mild digestive upset the most common complaint. Good short-to-medium-term safety; very-long-term data are thinner.
The evidence (8)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Majeed 2019 · Phytother Res | RCT | supports | low | RCT: standardized boswellia was safe and well-tolerated over the trial period. |
| Dejonckheere CS et al 2025 · study_type: observational | observational | supports | low | Meta-narrative review of 6 records (130 patients) on Boswellia serrata for radiation-induced cerebral edema/necrosis; reports 'Tolerability of BA was favorable, with mild gastrointestinal discomfort being reported most frequently.' |
| Abdel-Tawab 2011 · Clin Pharmacokinet | observational | supports | low | Narrative review, no new data: 'Compared to NSAIDs, it is expected that the administration of BSE is associated with better tolerability, which needs to be confirmed in further clinical trials.' Tolerability is stated as an expectation awaiting confirmation, not as a measured safety outcome; zero-weighted per CONVENTIONS §5. |
| Karimi M et al 2024 · study_type: meta-analysis | meta-analysis | tested-null | moderate | Systematic review and meta-analysis (5 RCTs, n=287 T2DM patients) of boswellia vs placebo/control for glycemic/lipid markers; background states herbal medicines used 'due to better safety and fewer adverse effects' but no pooled adverse-eve |
| Bannuru 2018 · Semin Arthritis Rheum | meta-analysis | supports | moderate | SR+meta-analysis: favourable safety profile relative to standard OA analgesics. |
| Yu 2020 · BMC Complement Med Ther | meta-analysis | supports | moderate | Systematic review: boswellia showed good tolerability; adverse events mild and mostly gastrointestinal. |
| Nguyen S, Kaufman M, Shetty M, Rovzar C, Friedlander A, Fredericson M 2025 · Am J Lifestyle Med | observational | supports | low | Narrative (non-systematic) review of lifestyle interventions for arthritis pain, PubMed/EMBASE/Cochrane/Google Scholar 2000-2025, with no pooling and no data of its own: 'A search of PubMed, EMBASE, Cochrane Library, and Google Scholar (2000 to 2025) identified randomized trials, meta-analyses, and cohort studies on nutrition, supplementation, physical activity, and sleep.' On tolerability it states: 'Supplements like curcumin, glucosamine, and Boswellia showed modest benefits with favorable safety,' and concludes 'Lifestyle medicine is safe, effective, and feasible to integrate into arthritis care.' ON-TOPIC for this claim but SECONDHAND and unquantified - no adverse-event rates, no withdrawal counts, no dose or duration, no comparator, and Boswellia is bundled with curcumin and glucosamine in the same sentence. It restates trials already appraised in the boswellia hub rather than adding independent observation, which is why it stays evidence_role: review at zero weight. Declared COI: 'The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.' Read from the PubMed abstract only - full text not retrievable (Europe PMC fullTextXML for PMC12618219 returned 0 bytes). Repairs a stored extract that had been truncated mid-word at 'No sp'. |
| Majeed A et al 2024 · study_type: RCT | RCT | supports | high | Double-blind, randomized, 3-arm, placebo-controlled trial (n=105 randomized/98 completed) of Boswellia serrata extract (Boswellin Super) 150mg or 300mg BID x90 days for knee OA; safety assessed via blood biochemistry, hematology, urinalysis |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.